The advent of immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), has revolutionized cancer therapy, yielding robust and durable responses in GC. This evidence concerns the gene PDCD1 and gastric cancer.